<DOC>
	<DOCNO>NCT00734682</DOCNO>
	<brief_summary>This Phase I study Nanoliposomal CPT-11 patient Recurrent high-grade glioma . Patients must histologically prove intracranial malignant glioma , include glioblastoma multiforme ( GBM ) , gliosarcoma ( GS ) , anaplastic astrocytoma ( AA ) , anaplastic oligodendroglioma ( AO ) , anaplastic mixed oligoastrocytoma ( AMO ) , malignant astrocytoma NOS ( otherwise specify ) . Patients wild type heterozygous UGT1A1*28 gene receive Nanoliposomal CPT-11 . The total anticipated accrual approximately 36 patient ( depend upon actual MTD ) . The investigator hypothesis new formulation CPT-11 increase survival see historical control recurrent gliomas CPT-11 encapsulate liposome nanoparticle , see reduce toxicity drug .</brief_summary>
	<brief_title>A Phase I Trial Nanoliposomal CPT-11 ( NL CPT-11 ) Patients With Recurrent High-Grade Gliomas</brief_title>
	<detailed_description>Patients recurrent malignant glioma receive Nanoliposomal CPT-11 time relapse . The dose adjust accord phase-1 dose escalation scheme . Patients receive drug intravenously every 3 week tumor progression excessive toxicity . Weekly follow occur ass toxicity DLT phase trial . Patients different dose escalation UGT1A1 6/6 versus UGT1A1 6/7 . Patients UGT 1A1 7/7 eligible . All patient must UGT 1A1 status know eligibility requirement . Patients follow toxicity progression , progression evaluate MR image every 6 week . Pharmacokinetics obtain first treatment cycle .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients histologically prove intracranial malignant glioma eligible . All patient must sign informed consent Patients must &gt; 18 year old , life expectancy &gt; 8 week . Patients must Karnofsky performance status &gt; 60 . Patients must recover toxic effect prior therapy Patients must adequate bone marrow function ( WBC &gt; 3,000/µl , ANC &gt; 1,500/mm3 , platelet count &gt; 100,000/mm3 , hemoglobin &gt; 10 gm/dl ) , adequate liver function ( SGOT bilirubin &lt; 2 time ULN ) , adequate renal function ( creatinine &lt; 1.5 mg/dL and/or creatinine clearance &gt; 60 cc/min ) Patients must show radiographic evidence tumor progression MRI CT scan . A scan performed within 14 day prior registration steroid dose stable least 5 day . Patients undergone recent resection recurrent progressive tumor eligible long follow condition apply : They recover effect surgery . Residual disease follow resection recurrent malignant glioma mandate eligibility study . Patients must fail prior radiation therapy Patients prior therapy include interstitial brachytherapy stereotactic radiosurgery must confirmation true progressive disease Women childbearing potential must negative ßHCG pregnancy test document within 14 day prior registration . Patients may treatment number prior relapse . Patients must significant medical illness investigator opinion adequately control Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy disease minimum 3 year ineligible . Patients must active infection serious intercurrent medical illness . Patients must pregnant/breast feeding must agree practice adequate contraception . Patients must disease obscure toxicity dangerously alter drug metabolism . Patients must receive prior therapy irinotecan . Patients 7/7 ( homozygous ) UGT1A1*28 genotyping exclude study . Patients receive enzymeinducing anticonvulsant enzyme induce drug exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Anaplastic Astrocytoma</keyword>
	<keyword>Anaplastic Oligodendroglioma</keyword>
	<keyword>Anaplastic Mixed Oligoastrocytoma</keyword>
	<keyword>Malignant Astrocytoma NOS</keyword>
	<keyword>Nanoliposomal CPT-11</keyword>
	<keyword>liposomal irinotecan</keyword>
</DOC>